Showing results (71-80 of 183) with videos related to

Sort By:
Pageof 19
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2009
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeksJoseph Gathe, Barbara A da Silva, Daniel E Cohen, et al.
AIDS (London, England)|November 25, 2011
Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudyAdrian Curran, Esteban Martinez, Maria Saumoy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 26, 2022
Doravirine Concentrations and Human Immunodeficiency Virus Type 1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine Plus Emtricitabine/Tenofovir AlafenamideSofía Scévola, Arkaitz Imaz, Mackenzie L Cottrell, et al.
Antiviral Therapy|June 21, 2011
Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovirMaria Saumoy, Jordi Ordoñez-Llanos, Esteban Martínez, et al.
The Journal of Antimicrobial Chemotherapy|September 4, 2016
Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patientsAdrian Curran, Jhon Rojas, Alfonso Cabello, et al.
AIDS Research and Human Retroviruses|December 21, 2010
Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adultsElena Ferrer, Luis del Rio, Esteban Martínez, et al.
AIDS (London, England)|April 21, 2011
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descentJing Yuan, Sheng Guo, David Hall, et al.
HIV Clinical Trials|August 28, 2007
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of responseDaniel Podzamczer, Martin S King, Cheri E Klein, et al.
HIV Medicine|April 27, 2011
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study)Daniel Podzamczer, J Andrade-Villanueva, B Clotet, et al.
The Journal of Antimicrobial Chemotherapy|December 20, 2014
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trialJosé Moltó, Marta Valle, Elena Ferrer, et al.
Pageof 19